Asset Sale Fuels Enzo Biochem; Verizon Q2 Earnings Beat
- July 25th, 2023
- 520 views
Shares of Enzo Biochem, Inc. (NYSE: ENZ) surged over 15% in pre-market trading following the successful completion of its asset sale to Laboratory Corporation of America Holdings (NYSE: LH).
The transaction involved the sale of substantially all assets used in the operation of Enzo Clinical Labs in the New York metropolitan region, with an impressive aggregate purchase price of $113,250,000 in cash, subject to customary closing adjustments. As part of the deal, Enzo Biochem will halt its clinical laboratory operations.
In pre-market, $ENZ is currently trading at $1.63, marking a notable increase of $0.27 (+19.85%).
In other news, Verizon Communications Inc. (NYSE: VZ) has released its second-quarter 2023 financial results, reporting adjusted earnings per share (EPS) of $1.21, surpassing the consensus estimate of $1.16.
Looking ahead, Verizon is projecting for the full-year 2023 adjusted EPS to be in the range of $4.55 to $4.85, while analysts are expecting $4.68 for the period
$VZ is currently trading at $34.90 in pre-market, up $0.92 (+2.71%).
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Tags
Post Your Comments
Want To Find Some News?
Recent Posts
-
NJCP National Football Conference Names David Dalton Head Coach of Salt Lake Yeti
February 06th, 2026FDA Takes New Approach to "No Artificial Colors" Claims
February 06th, 2026NJCP National Football Conference Announces Micah Deckart as Head Coach of the Idaho Outlaws
February 05th, 2026
Member Login